NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

China's National Medical Products Administration (NMPA) released the 109th Catalog of Reference Listed Drugs for Chemical Generic Drugs, adding 30 new product specifications and supplementing information for 24 product specifications…

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations
CompanyDrug

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC
CompanyDrug

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Roche's Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year
CompanyDrug

Roche’s Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo
CompanyDrug

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

Novo Nordisk A/S (NYSE: NVO) announced that it has acquired three brand‑new obesity research and development programs from New York‑based biotech company Kallyope. Jacob Petersen, head of global research at Novo Nordisk, wrote in a LinkedIn post that one program…

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation
CompanyDeals

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength
CompanyDeals

Shanghai Shenqi Medical Partners with Bio-heart to Commercialize BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent – Ultra‑Thin 90μm Strut Design Targets Deliverability and Radial Strength

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery
CompanyDeals

HanX Biopharmaceuticals Signs Long‑Term Strategic Cooperation and AI Platform License with XtalPi Science – AI for Science to Power Antibody Design and Innovative Molecule Discovery

AbbVie Taps Iambic's AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology
CompanyDeals

AbbVie Taps Iambic’s AI Platform in Multi-Year Collaboration – Enchant v3 Multimodal Model Targets First-in-Class Small Molecules in Immunology, Neuroscience and Oncology

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Yifan Pharmaceutical Secures China Rights to Boryung's Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations
CompanyDeals

Yifan Pharmaceutical Secures China Rights to Boryung’s Taxotere – Docetaxel Injection Commercialization Deal Covers Promotion, Distribution and Market Operations

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) and Boryung Corporation (KRX: 003850) of South Korea announced a partnership agreement under which Yifan Pharmaceutical has obtained the general agency rights for Taxotere…

Biokin's Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC
CompanyDeals

Biokin’s Bispecific ADC Izalontamab Bretecan Wins Eighth Breakthrough Therapy Designation in China – PD-1 Combo Targets First-Line PD-L1-Positive TNBC

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models
CompanyDeals

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive
CompanyDeals

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies
CompanyDeals

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

- Advertisement -
Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing
CompanyDeals

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the "15th Five‑Year Plan for Pharmaceutical Industry Development" (the "Plan"), setting quantitative industry targets…

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

China's NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies
Policy / Regulatory

China’s NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies

More News

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity
Others

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Hansoh's Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
CompanyDrug

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance
CompanyDrug

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia
CompanyDrug

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion
Others

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Novo Nordisk's Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe
CompanyDrug

Novo Nordisk’s Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe

Alexion's Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca's Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle
CompanyDrug

Alexion’s Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca’s Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle

Show More